Harmony Biosciences (HRMY) awards 212,241 stock options to COO Anastasiou

Rhea-AI Filing Summary

Harmony Biosciences Holdings, Inc. reported that Chief Operating Officer Peter Anastasiou received a grant of stock options covering 212,241 shares of common stock. The options have an exercise price of $27.74 per share and expire on April 2, 2036.

According to the grant terms, 25% of the underlying shares vest on April 2, 2027, with the remaining options vesting on a quarterly basis until the fourth anniversary of the grant date, contingent on his continued service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Anastasiou Peter

Role CHIEF OPERATING OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	212,241	$0.00	--

Holdings After Transaction: Stock Option — 212,241 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 212,241 options Exercise price: $27.74 per share Expiration date: April 2, 2036 +1 more

4 metrics

Option grant size 212,241 options Stock option award to COO Peter Anastasiou

Exercise price $27.74 per share Exercise price for granted stock options

Expiration date April 2, 2036 Option term end date

Initial vesting date April 2, 2027 25% of options vest on this date

Key Terms

Stock Option, exercise price, grant date, vesting

4 terms

Stock Option financial

"The stock option vests with respect to 25% of the underlying shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price": "27.7400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

grant date financial

"until the fourth anniversary of the grant date, subject to the Reporting Person's continued service"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vesting financial

"with the remaining shares vesting ratably on a quarterly basis thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anastasiou Peter

(Last) (First) (Middle)

C/O HARMONY BIOSCIENCES HOLDINGS, INC.

630 W GERMANTOWN PIKE, SUITE 215

(Street)

PLYMOUTH MEETING PENNSYLVANIA 19462

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$27.74	04/02/2026		A		212,241		(1)	04/02/2036	Common Stock	212,241	$0	212,241	D

Explanation of Responses:

1. The stock option vests with respect to 25% of the underlying shares on April 2, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.

	/s/ Christian Ulrich, Attorney-in-Fact	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Harmony Biosciences (HRMY) report for Peter Anastasiou?

Harmony Biosciences reported that COO Peter Anastasiou received a grant of stock options for 212,241 shares of common stock. These options were awarded as a compensation-related acquisition rather than an open-market purchase or sale of existing Harmony Biosciences shares.

What are the key terms of Peter Anastasiou’s Harmony Biosciences (HRMY) stock options?

The stock options cover 212,241 underlying shares of Harmony Biosciences common stock at an exercise price of $27.74 per share. They expire on April 2, 2036, giving the executive a long-dated incentive aligned with the company’s future share price performance.

How do the Harmony Biosciences (HRMY) options granted to Peter Anastasiou vest?

The options vest over time. Twenty-five percent of the underlying shares vest on April 2, 2027. The remaining options then vest ratably on a quarterly basis until the fourth anniversary of the grant date, provided he continues his service with Harmony Biosciences.

Is Peter Anastasiou’s Harmony Biosciences (HRMY) option grant an open-market buy or sale?

The transaction is a grant or award of stock options, not an open-market buy or sale. It represents a compensation-related acquisition of derivative securities, giving the COO the right to purchase Harmony Biosciences common stock at a set exercise price in the future.

How many Harmony Biosciences (HRMY) options does Peter Anastasiou hold after this grant?

Following this grant, Peter Anastasiou holds 212,241 stock options directly, according to the filing. Each option is exercisable for one share of Harmony Biosciences common stock, subject to the specified vesting schedule and the long-term expiration date in 2036.